Kido et al. proposed that advanced glycation end-products (AGEs), which is accumulated in patients with CKD, increases fibroblast growth factor 23 (FGF23) and its receptor Klotho-mediated suppression of insulin/IGF-1, leading to inhibition of S differentiation. The gene discussed is INS; the disease is chronic kidney disease.